Adrovance

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
20-02-2024
Opinber matsskýrsla Opinber matsskýrsla (PAR)
19-05-2011

Virkt innihaldsefni:

colecalciferol, alendronic acid (as sodium trihydrate)

Fáanlegur frá:

N.V. Organon

ATC númer:

M05BB03

INN (Alþjóðlegt nafn):

alendronic acid, colecalciferol

Meðferðarhópur:

Drugs for treatment of bone diseases

Lækningarsvæði:

Osteoporosis, Postmenopausal

Ábendingar:

Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Adrovance reduces the risk of vertebral and hip fractures.

Vörulýsing:

Revision: 25

Leyfisstaða:

Authorised

Leyfisdagur:

2007-01-04

Upplýsingar fylgiseðill

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE USER
ADROVANCE 70 MG/2,800 IU TABLETS
ADROVANCE 70 MG/5,600 IU TABLETS
alendronic acid/colecalciferol
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
It is particularly important to understand the information in section
3 before taking this
medicine.
WHAT IS IN THIS LEAFLET
1.
What ADROVANCE is and what it is used for
2.
What you need to know before you take ADROVANCE
3.
How to take ADROVANCE
4.
Possible side effects
5
How to store ADROVANCE
6.
Contents of the pack and other information
1.
WHAT ADROVANCE IS AND WHAT IT IS USED FOR
WHAT IS ADROVANCE?
ADROVANCE is a tablet containing the two active substances, alendronic
acid (commonly called
alendronate) and colecalciferol known as vitamin D
3
.
WHAT IS ALENDRONATE?
Alendronate belongs to a group of non-hormonal medicines called
bisphosphonates. Alendronate
prevents the loss of bone that occurs in women after they have been
through the menopause, and helps
to rebuild bone. It reduces the risk of spine and hip fractures.
WHAT IS VITAMIN D?
Vitamin D is an essential nutrient, required for calcium absorption
and healthy bones. The body can
only absorb calcium properly from our food if it has enough vitamin D.
Very few foods contain
vitamin D. The main source is through exposure to summer sunlight,
which makes vitamin D in our
skin. As we get older our skin makes less vitamin D. Too little
vitamin D may lead to bone loss and
osteoporosis. Severe vitamin D deficiency may cause muscle weakness
which can lead to falls and 
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ADROVANCE 70 mg/2,800 IU tablets
ADROVANCE 70 mg/5,600 IU tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ADROVANCE 70 mg/2,800 IU tablets
Each tablet contains 70 mg alendronic acid (as sodium trihydrate) and
70 micrograms (2,800 IU)
colecalciferol (vitamin D
3
).
_Excipients with known effect_
Each tablet contains 62 mg lactose (as lactose anhydrous) and 8 mg
sucrose.
ADROVANCE 70 mg/5,600 IU tablets
Each tablet contains 70 mg alendronic acid (as sodium trihydrate) and
140 micrograms (5,600 IU)
colecalciferol (vitamin D
3
).
_Excipients with known effect _
Each tablet contains 63 mg lactose (as lactose anhydrous) and 16 mg
sucrose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
ADROVANCE 70 mg/2,800 IU tablets
Modified capsule-shaped, white to off-white tablets, marked with an
outline of a bone image on one
side, and '710' on the other.
ADROVANCE 70 mg/5,600 IU tablets
Modified rectangle-shaped, white to off-white tablets, marked with an
outline of a bone image on one
side, and '270' on the other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
ADROVANCE is indicated for the treatment of postmenopausal
osteoporosis in women at risk of
vitamin D insufficiency. It reduces the risk of vertebral and hip
fractures.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ _
The recommended dose is one tablet once weekly.
Patients should be instructed that if they miss a dose of ADROVANCE
they should take one tablet on
the morning after they remember. They should not take two tablets on
the same day but should return
to taking one tablet once a week, as originally scheduled on their
chosen day.
Due to the nature of the disease process in osteoporosis, ADROVANCE is
intended for long-term use.
3
The optimal duration of bisphosphonate treatment for osteoporosis has
not been established. The need
for continued treatment should be re-evaluated periodically based on
the benefits and potential risks of
ADROVANC
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 20-02-2024
Vara einkenni Vara einkenni búlgarska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla búlgarska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 20-02-2024
Vara einkenni Vara einkenni spænska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla spænska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 20-02-2024
Vara einkenni Vara einkenni tékkneska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla tékkneska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 20-02-2024
Vara einkenni Vara einkenni danska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla danska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 20-02-2024
Vara einkenni Vara einkenni þýska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla þýska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 20-02-2024
Vara einkenni Vara einkenni eistneska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla eistneska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 20-02-2024
Vara einkenni Vara einkenni gríska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla gríska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 20-02-2024
Vara einkenni Vara einkenni franska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla franska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 20-02-2024
Vara einkenni Vara einkenni ítalska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla ítalska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 20-02-2024
Vara einkenni Vara einkenni lettneska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla lettneska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 20-02-2024
Vara einkenni Vara einkenni litháíska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla litháíska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 20-02-2024
Vara einkenni Vara einkenni ungverska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla ungverska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 20-02-2024
Vara einkenni Vara einkenni maltneska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla maltneska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 20-02-2024
Vara einkenni Vara einkenni hollenska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla hollenska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 20-02-2024
Vara einkenni Vara einkenni pólska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla pólska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 20-02-2024
Vara einkenni Vara einkenni portúgalska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla portúgalska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 20-02-2024
Vara einkenni Vara einkenni rúmenska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla rúmenska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 20-02-2024
Vara einkenni Vara einkenni slóvakíska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 20-02-2024
Vara einkenni Vara einkenni slóvenska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvenska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 20-02-2024
Vara einkenni Vara einkenni finnska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla finnska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 20-02-2024
Vara einkenni Vara einkenni sænska 20-02-2024
Opinber matsskýrsla Opinber matsskýrsla sænska 19-05-2011
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 20-02-2024
Vara einkenni Vara einkenni norska 20-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 20-02-2024
Vara einkenni Vara einkenni íslenska 20-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 20-02-2024
Vara einkenni Vara einkenni króatíska 20-02-2024

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu